GSK 2302024A

Drug Profile

GSK 2302024A

Alternative Names: GSK2302024A; WT1-A10+AS15 ASCI

Latest Information Update: 29 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 01 Aug 2014 GlaxoSmithKline terminates phase II trial in Breast cancer (Neoadjuvant therapy, Combination therapy) in Belgium, France, Germany, Italy, Russia, the US and the UK (NCT01220128)
  • 31 Jul 2013 Phase II clinical trials in Breast cancer (neoadjuvant, in combination with standard therapy) in Belgium, Russia and USA prior to July 2013 (IM) (NCT01220128)
  • 01 Apr 2011 Phase-II clinical trials in Breast cancer (Neoadjuvant therapy, Combination therapy) in Germany (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top